<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01658722</url>
  </required_header>
  <id_info>
    <org_study_id>AAB-001-ALZ-3300</org_study_id>
    <nct_id>NCT01658722</nct_id>
  </id_info>
  <brief_title>Retrieval of Patient Information After Discontinuation</brief_title>
  <acronym>RAPID</acronym>
  <official_title>A Phase 3b Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies ELN15727-301 and 302 But Did Not Enroll in Study ELN115727-351</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>JANSSEN Alzheimer Immunotherapy Research &amp; Development, LLC</source>
  <brief_summary>
    <textblock>
      A Phase 3b, Study of Subjects With Alzheimer's Disease Who Discontinued Treatment in
      Bapineuzumab Phase 3 Clinical Studies (ELN115727-301/302/351) or Who Completed Studies
      ELN115727-301 and 302 but did not Enroll in Study ELN115727-351.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dependence Scale</measure>
    <time_frame>4 years</time_frame>
    <description>Caregiver's assessment of a patient's need for assistance</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">169</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>Long term follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bapineuzumab</intervention_name>
    <arm_group_label>Observational</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects with Alzheimer's disease who discontinued treatment in bapineuzumab Phase 3
        clinical studies (ELN115727-301/302/351) or who completed studies ELN115727-301 or 302 but
        did not enroll in study ELN115727-351
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        1. Signed, dated, and written informed consent obtained from the subject and/or the
             subject's legally acceptable representative (LAR, if applicable) in accordance with
             local regulations.

          2. Signed, dated, and written informed consent, obtained from the subject's caregiver in
             accordance with local regulations.

          3. Subject must have participated in the Study 301, 302, or 351 and have received at
             least 1 dose of study treatment (bapineuzumab or placebo).

          4. Subject must have been off treatment for at least 12 months prior to Visit 1.

          5. Subjects must have a primary caregiver for the duration of the study.

          6. Subject's caregiver must have the ability to assess the subject and answer questions
             over the phone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 12, 2012</study_first_submitted>
  <study_first_submitted_qc>August 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2012</study_first_posted>
  <last_update_submitted>August 31, 2015</last_update_submitted>
  <last_update_submitted_qc>August 31, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

